Skip to main content
SpringerLink
Log in

Dose-dense chemotherapy cost effective for ovarian cancer

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Gynecologic Oncology Group protocol 262

Reference

  • Seagle BL, et al. Cost-effectiveness analysis of dose-dense versus standard intravenous chemotherapy for ovarian cancer: An economic analysis of results from the Gynecologic Oncology Group protocol 262 randomized controlled trial. Gynecologic Oncology : 10 Feb 2017. Available from: URL: http://doi.org/10.1016/j.ygyno.2017.02.014

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dose-dense chemotherapy cost effective for ovarian cancer. PharmacoEcon Outcomes News 772, 15 (2017). https://doi.org/10.1007/s40274-017-3763-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-3763-8

Search

Navigation